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Background: Meeting specific guideline targets is associated with improved survival rates and reduced
hospitalizations in the dialysis population. This prospective work evaluated the adequacy of hemodialysis quality
indicators in an in-center hemodialysis population with severe comorbidities, and assessed whether clinical practice
could impact intermediate outcomes.
Methods: All the chronic hemodialysis patients treated in Rouen University Hospital hemodialysis Unit between
January 2009 and April 2010 were included in this observational study. Every quarter, mean levels and prevalence of
conformity were collected for the following indicators: anemia, dialysis dose, serum calcium and phosphorus, PTH,
25OH-vitamin D, albumin, serum bicarbonate, LDL-cholesterol, serum β2-microglobulin, systolic and diastolic blood
pressure, intradialytic hypotension and vascular access. Conformity of quality-of-care indicators was determined
according to targets defined by international guidelines, whenever available.
Results: Altogether, 124 patients were included in the study. Thirty-three patients were evaluated during the entire
follow-up period. An improvement in the percentage of conformity was observed for hemoglobin, dialysis dose,
phosphates, PTH, serum bicarbonate and β2-microglobulin in the global population. Failure to improve conformity
rates for several indicators, including serum albumin, was found, possibly depending on patients’ comorbidities
rather than on quality of care.
Conclusion: Overall, this study shows that following quality-of-care indicators can improve clinical practice by
identifying center-specific weaknesses, prompting the establishment of corrective measures. Finally, we suggest that
the definition and targets of some indicators, especially hypertension and LDL-cholesterol, be reviewed, since
evidence of their association with mortality is not demonstrated.
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Hemodialysis patients present persistent high morbidity
and mortality rates, in spite of the promising technical
advances developed over the last 15 years. In Europe,
survival rates of patients who begun hemodialysis
between 2002 and 2006 were 78.7% and 65.8% after 1 year
and 2 years, respectively [1]. However, survival improved
by 10%, between the patients who started hemodialysis
in 1997–2001 and those who started in 2002–2006. This
improvement, despite increases in the age and prevalence
of diabetes, mainly reflects the relative importance of the
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reproduction in any medium, provided the orTwo large observational studies in prevalent and incident
patients have shown that the increasing number of
unfulfilled therapeutic targets was associated with
higher mortality and hospitalization rates [2,3]. The
main quality-of-care indicators are well defined [4-6].
Numerous studies have documented that an increased
risk for death and hospitalization was associated with
lower levels of dialysis adequacy, increased anemia,
lower serum albumin values, and the use of a vascular
access other than an arteriovenous fistula (AVF) for
hemodialysis. Consequently, clinical practice guidelines
such as the Kidney Disease Outcomes Quality Initiative
(KDOQI) or the European Best Practice Guidelines
(EBPG) were developed in order to improve the quality of
care and outcomes of hemodialysis patients [7].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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monitoring of established quality-of-care indicators in
an in-center hemodialysis population, and to identify the
indicators that were not achieved. When it was necessary,
a centre-specific intervention was decided, to improve our
results concerning these indicators. We critically analyze
these results and the impact of monitoring quality-of-care
indicators in our clinical practice. Based on these practical
issues, we suggest alternative quality-of-care indicators
that can easily be monitored, and may be relevant because
of their association with morbidity and mortality in large
observational studies.
Methods
This monocentric prospective study included every
prevalent and incident patient admitted in Rouen University
Hospital Hemodialysis Unit, from January 2009 through
April 2010. Patients with acute renal failure were excluded.
All patients received dialysis with a Fresenius 5008
dialysis machine (Fresenius Medical Care, Bad Homburg,
Germany) and biocompatible high-flux membranes
(Kuf > 40 ml/h/mmHg) with surface area above 1.8 m2.
Prevalent patients had an AVF every time it was possible.
For incident patients, tunnelized catheters were placed
in the days following the initiation of hemodialysis and
were converted to AVF as soon as possible. The traditional
regimen consisted of 4 hours dialysis sessions, three
times a week. Patients were treated with conventional
hemodialysis or hemodiafiltration. Blood flow rate and
dialysate flow rate were 400 ml/min and 800 ml/min,
respectively. The dialysis dose (Kt) was available for
each seance via the on-line clearance monitoring module
(OCM), measuring ionic dialysance. The volume of distri-
bution of urea was estimated using bio-impedancemetry
(BCM; body composition monitor, Fresenius Medical
care, Bad Homburg, Germany) [8]. For the patients on
hemodiafiltration, the infusion volume was also collected.
Isothermic dialysis, by means of a blood temperature
monitor (Module BTM, available on Fresenius 5008
machines), and isonatremic dialysis were systematically
performed [9,10]. A dialysate calcium of 1.5 mmol/l was
used for the majority of patients, while 1.75 mmol/l was
never used. The bicarbonate content of the dialysate
was individualized and adjusted to achieve a pre-dialysis
bicarbonate level between 20 and 24 mmol/l.
When malnutrition was diagnosed, patients received
nutritional counselling from a qualified dietician. Nutrition
supplements were prescribed if nutritional counselling did
not achieve an increase in nutrient intake to a level covering
minimum recommendations. Intradialytic parenteral nutri-
tion was prescribed in the patients who experienced dietary
support and/or oral supplement failure, in particular in
hospitalized patients with acute inflammatory state or
inflammatory bowel disease (Smofkabiven 1100 kcal,Fresenius Kabi, France, the dose was increased at 1600
kcal per dialysis session in case of good tolerance). All
patients received calcifediol once a week, the dose
depending on the severity of 25OH-vitamin D deficiency.
Statins were systematically prescribed.
For patients with high blood pressure (BP > 140/
90 mmHg) despite antihypertensive multitherapy, after
reduction of the dry weight when necessary, ambulatory
blood pressure monitoring was performed to confirm
hypertension before prescribing an additional antihyper-
tensive agent.
Changes in the prescription of erythropoiesis stimulating
agents (ESA), phosphate binders and bicarbonate dialysate
concentration were carried out every month in parallel.
Before adjusting ESA, intravenous iron supplementation
was performed, if needed, to reach a ferritinemia between
200 and 500 μg/l and transferrin saturation > 20%.
The following indicators were collected monthly:
Hemoglobin, ESA dose, serum phosphorus, calcium, albu-
min and bicarbonate concentrations. Unless specified,
the following indicators were recorded every quarter:
– Serum parathyroid hormone, serum 25OHvitD
(every 6 months), serum β2-microglobulin.
– Total cholesterol and LDL-cholesterol.
– Technique of renal replacement therapy:
hemodialysis, post-dilution on-line hemodiafiltration,
pre-dilution on-line hemodiafiltration, daily
post-dilution on-line hemodiafiltration, hemofiltration.
– Pre-dialysis systolic and diastolic BP of the 10 last
dialysis sessions. The mean of the 10 values was
used to determine whether or not the target was
achieved.
– Dialysis dose: On-line urea clearance estimation
makes it possible to calculate the dialysis dose Kt and
thus allows for the estimation of the « single-pool »
Kt/V for each session [8]. Kt/VBCM of the 10 last
dialysis sessions were collected. The mean of the 10
values was used to determine whether or not the
target was achieved (Kt/VBCM > 1.4).
– Percentage of dialysis sessions with symptomatic
intradialytic hypotension (IDH), defined by a decline
in BP associated with specific symptoms, with the
need to stop ultrafiltration and/or saline infusion,
taking into account the last 10 sessions.
Prevalence of conformity was defined by the percentage
of patients who attained targets for each indicator. Every
quarter, the mean value and the prevalence of conformity
for each quality-of-care indicator were calculated in the
global population and in the patients who remained in the
center between January 2009 and April 2010.
This study did not require ethical approval according
to French research legislation.
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guidelines including KDOQI and EBPG guidelines, and by
evidence available in the literature in the absence of
existing guidelines [5,11-13]. When conformity rates were
below those found in guidelines or literature, a decision
was made to initiate corrective measures. For the main
indicators, quarterly meetings were organized, where
individual corrective measures were decided for the
patients who did not attain the target.
Statistical analysis: Comparison between initial (January
2009) and follow-up (April 2010) conformity rates was
made using chi-square analysis. P < 0.05 was considered to
indicate significance.
Results
Overall, 124 patients were included in the study. 33
patients were evaluated during the entire follow-up period.
Demographic data are listed in Table 2.
Quality indicators
Table 3 shows the results corresponding to the time-points
of January 2009 (baseline) and April 2010 (follow-up, after
corrective measures) in the total population and in the 33
patients who were hemodialyzed in our center during the
entire study period. The trend for each indicator was the
same whether or not the incident patients were being
taken into account in the analysis. For each indicator,
evolution of mean levels (lines) and conformity rates
(histograms) during the 6 quarters are shown in Figure 1.
We compared serum phosphorus between the patients
treated by haemodialysis (n = 17, mean phosphorus:Table 1 Quality-of-care indicators, targets and references
Field Clinical indicator Frequency Clinical per
Anemia Hemoglobin (Hb, g/dl) M % of patient
Dialysis dose Kt/VBCM (single-pool) S % of patient
Kt (liters) S % of patients
Bone metabolism Phosphorus (mmol/l) M % of patient
Calcium (mmol/l) M % of patient
PTH (pg/ml) Q % of patient
25(OH)vitD (nmol/l) Q % of patient
Nutrition Albumin (g/l) M % of patient
Serum Bicarbonate (mmol/l) M % of patient
LDL-cholesterol (mmol/l) Q % of patient
Vascular access Arteriovenous fistula % of patient
Middle molecule
removal
Infusion Volume (Liters) S Infusion volu
β2-microglobulin (mg/l) Q % of patient
Hemodynamics Blood pressure S % of patient
Hemodynamics instability % of dialysis
: Targets different from available clinical practice guidelines.
Frequency : S = Values collected each dialysis session ; M =monthly ; Q = quarterly.1.61 mmol/l) and those treated by post-dilution haemodia-
filtration (n = 29, mean phosphorus: 1.41 mmol/l) between
January and April 2010. We observed a trend for lower
serum phosphorus levels in the « hemodiafiltration »
group compared to the « hemodialysis » group (p = 0.09).
Discussion
CKD is associated with increased mortality, mainly
attributable to cardiovascular events. In ESRD patients,
optimization of dialysis quality and cardiovascular risk
factors is consequently a major issue, and monitoring
of specific indicators is therefore mandatory. A relevant
quality-of-care indicator should have two main character-
istics: it should be associated with a lower risk of death,
and attainment of the target should be possible thanks to
medical practice changes. In this study over a 12-month
period, an improvement in the percentage of conformity
to predefined targets was observed for hemoglobin,




The percentage of patients who achieved a Hb level
within the 10–13 g/dl target range increased from 60%
to 80%, which was in accordance with the results
obtained from the national data system « REIN 2008 ».
This improvement may be due to the increase of
erythropoietin doses and to the optimization of the iron
status. In terms of mortality, meta-analyses did not show
any statistically significant difference between higher andformance measures References
s with 10 < Hb < 13 *
s with Kt/VBCM > 1.4 EPBG 2002
with Kt > 40l (women), with Kt > 45l (men) Lowrie et al. [14-16]
s with 1.13 < P < 1.78 KDOQI Bone metabolism 2003
s with 2.10 < Ca < 2.38 KDOQI Bone metabolism 2003
s with 150 < PTH < 300 KDOQI Bone metabolism 2003
s with 72 < vitD < 200 *
s with albumin > 35 *
s with 20 < HCO3- < 24 *
s with LDL < 2.6 *
s with catheters < 7% Dopps [4]
me > 15 L *
s with β2m < 27.5 Cheung et al. [17]
s with pre-dialysis BP < 140/90 mmHg KDOQI 2005 [5]
sessions with symptomatic IDH
Table 2 Characteristics of the study population (n = 124)
Values are n (%), unless otherwise specified
Age (mean ± SD) 69.1 ± 14
Men 72 (58%)
Women 52 (42%)
Time on hemodialysis (mean ± SD) 32.6 ± 42
Comorbidities
Diabetes Mellitus 59 (47.6%)
Hypertension 99 (79.8%)
Dyslipidemia 71 (57.3%)
Ischemic Cardiomyopathy 50 (40.3%)
Lower Limb arteriopathy 31 (25%)
Charlson Score (mean ± SD) 8 ± 2.6
Renal Disease
Diabetes Nephropathy 35 (28.2%)
Vascular-Hypertensive 29 (23.4%)
Polycystic-kidney disease 5 (4%)
Glomerular 12 (9.7%)
Others 43 (34.7%)
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allows for relative flexibility in medical decision making
and takes into account variability between patients’
comorbidities, prognosis, functional status, and respon-
siveness to ESA therapy. In in-center hemodialysis
patients, it is more difficult to achieve hemoglobin targets
because of comorbidities, including numerous diseases
with inflammatory state, responsible for ESA resistance.
Accordingly, we found no correlation between erythropoetin
doses and the percentage of conformity for anemia.
Vascular access management
Our percentage of patients hemodialysed with catheters
did not decrease. Indeed, the majority of incident patients
did not start dialysis with AVF. Our conformity rate
for vascular access was higher than 80% in 2009 when
we excluded the incident patients who had initiated
hemodialysis for less than three months, whereas it
was lower than 80% when these patients were included
in the analysis. Another reason is that there is a lack
of suitable vessels to create AVFs because of an aging
and diabetic population. Data from « REIN 2008 »,
that include both in-patients and out-patients, showed
that 16.5% of 22852 patients were hemodialysed via
catheters in France in 2008. In a cohort study of 78420
maintenance hemodialysis patients comprising approxi-
mately 26% of the US hemodialysis population, Lacson
Jr et al. found a 39% increased risk of death with catheters
compared with fistulas, making the vascular access the
second most important actionable variable associated with
mortality after albumin [17]. Thus, the first measure toimprove our percentage of patients dialysed on AVF
would be to avoid the late referral of the patient to the
nephrologist, which has been associated with increased
catheter use. The second would be to shorten the delay
before the creation of the AVF after initiation of dialysis.
Dialysis dose management
The prevalence of conformity for dialysis dose increased
regularly, up to 98.4% in April 2010. The few patients
who did not reach the Kt/VBCM target had either a high
urea distribution volume, or a dysfunction of their vascular
access (catheter dysfunction or immature fistula). Results
from « REIN 2008 » showed that 78.4% of 13451 patients
had a Kt/V > 1.2. We used high blood and dialysate flow
rates, membranes with a large surface area, and performed
high-flux dialysis according to the results of the HEMO
Study [19]. The prevalence of patients using hemodia-
filtration increased during follow-up, which is a potential
explanation for these results. Indeed, small solute dialysis
dose delivered by hemodiafiltration is higher than that
delivered by hemodialysis, because of increasing convective
clearance. Canaud et al. showed that high-efficiency
hemodiafiltration (infusion volume > 15 liters) had a
positive impact on survival compared to patients treated
by high-flux hemodialysis [20]. Articles suggest that
dosing of dialysis should be based on the volume of
blood cleared (Kt), rather than on Kt/V, which can lead to
under-dialysis in women and small men by underestimating
the hemodialysis dose [14,15,21]. Kt can easily be
monitored during each treatment with the OCM device.
Non evidence-based quality-of-care indicators
Hypertension management
Hypertension is a major cardiovacular risk factor in ESRD
patients. In our study, the prevalence of conformity for
systolic blood pressure was not improved. However,
hypertension guidelines in hemodialysis patients are
not currently based upon evidence. KDOQI guidelines
concerning blood pressure target ranges were extrapolated
from the general population [5]: Predialysis and post-
dialysis BP goals should be <140/90 mm Hg and <130/
80 mmHg respectively, provided that there is no substantial
orthostatic hypotension and that these levels are not
associated with substantial and symptomatic intradialytic
hypotension. Tentori et al., in a retrospective analysis
in 13792 incident hemodialysis patients, showed that
following the guideline for predialysis blood pressure
(BP) measurements was associated with increased mortality
[5]. Zager et al. found a « U » curve relationship between
post-dialysis SBP and cardiovascular mortality in more
than 5400 hemodialysis patients. SBP < 110 mmHg
and > 180 mmHg, and DBP > 90 mmHg were associated
with poor outcomes [16]. Indeed, relative hypotension is a
potent marker of mortality in ESRD patients, probably










N patients 65 69 33 33
Sex ratio 1.09 1.33 0.89 0.89
Dialysis Vintage (months) 41.3 40 54.7 68.5
Dialysis technique 78,5% 37.1% 67.6% 8.8%
Hemodialysis 0% 1.4% 0% 0%
Hemofiltration 4,6% 4.3% 5.9% 5.9%
13,8% 52.9% 20.6% 85.3%
Daily HDF
Post-dilution HDF 3,1% 4.3% 5.9% 0%
Pre-dilution HDF
Hemoglobin 11.3/55.4% 10.9/65.2% NS 11/50% 11,1/67,6 0.03
EPO doses UI/Kg/week 111.3 133.8 106 126.4
Albumin (g/dl) 35/53.1% 34/44.9% NS 34,7/52,9% 33,6/38,2% NS
Calcium (mmol/l) 2.28/58.4% 2.30/60.8% NS 2,27/47% 2,30/47% NS
Phosphates (mmol/l) 1.43/44.6% 1.48/60.3% 0.008 1.36/44% 1.45/55.9% NS
PTH (pg/ml) 442/22% 315/43.7% 0.0005 389/14.7% 271/35.3% 0.01
25OHvitD (nmol/l) 94.5/43% 94.9/67.6%
HCO3- (mmol/l) 24/50.8% 22.7/81.1% <0.0001 24.3/50% 22.7/82.4% <0.0001
LDL-cholesterol (mmol/l) 1.99/79.4% 1.95/80% NS 2.1/76.5 1.95/70.6% NS
B2microglobulin (mg/l) 34.78/28.2% 26.3/48.5% 0.001 32.6/29.4% 28.5/38.2% NS
Pre-dialysis SBP (mmHg) 142/52.3% 138.4/51.4% NS 138.9/58.8% 137.3/58.8 NS
Pre-dialysis DBP (mmHg) 64/98.5% 62.3/100% NS 62.3/100% 63.3/100% NS
Kt (L) 55.6/95.1% 60.1/97% NS 57.2/88.2% 63.6/97% 0.002
Kt/V 1.94/90% 2.19/98.4% <0.0001 2.07/85.3% 2.37/94% 0.03
Vascular access (catheters < 7%) 78.5% AVF 74.3% AVF NS 85.3% AVF 88.2% AVF NS
21.5% catheter 25.7% catheter 14.7% catheter 11.8% catheter
% of dialysis sessions with IDH 11.8% 12.2% NS 9.1% 10.6% NS
*: Comparison of the conformity rates. A p value < 0.05 was considered statistically significant.
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target should be used as a quality-of-care indicator for
hemodialysis patients. In the future, targets related to
ambulatory BP measurements (ABPMs) or home BP
measurements may be used. ABPMs were found to be
superior to dialysis unit recordings in predicting outcomes
[22]. In a prospective cohort study conducted in 150 chronic
hemodialysis patients, self-measured and ambulatory
systolic BP between 125 and 145 mmHg, and between
115 and 125 mmHg, respectively, were associated with a
decreased risk of death [23].
Nutrition management
No improvement was observed in the mean serum albumin
level and the percentage of conformity, which is around
50%. Our results were different from those reported in «
REIN 2008 », where 64.9% of 24436 patients had analbumin > 35 g/l, presumably because of increased
comorbidities in our in-center patients.
Albumin level showed the strongest association with
mortality compared with other predictor variables in
several large observational studies [24]. However, when
adjusted to other major comorbidities, hypoalbuminemia
was not significantly associated with mortality [25]. Since
comorbid medical conditions may decrease albumin
synthesis in the liver, hypoalbuminemia is a non-specific
marker of denutrition and a difficult-to-modify patient
factor, better associated with patient comorbidities than
with poor quality of care [26]. In a randomized controlled
study involving 180 patients with albuminemia below
37 g/l, a nutrition intervention tailored to patient-
specific barriers resulted in modest improvements in
albumin levels, regardless of levels on inflammatory
markers [27]. In our study, albumin was measured
Figure 1 Quality indicators: Evolution of mean levels (lines) and conformity rates (histograms) during the 6 quarters. Hemoglobin (g/dl) ;
SBP and DBP : Systolic and Diastolic Blood Pressure (mmHg) ; Serum Calcium (mmol/l) ; Serum Albumin (g/l) ; Serum Phosphate (mmol/l) ; PTH
(pg/ml) ; 25OHvitaminD (nmol/l) ; Serum Bicarbonate (mmol/l) ; LDL-cholesterol (mmol/l) ; β2-microglobulin (mg/l).
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as the gold-standard method. The threshold used by the
KDOQI (40 g/l) to detect hypoalbuminemia was not
chosen because the bromocresol-green method used for
KDOQI guidelines overestimates albuminemia [28].
The conformity rate for serum bicarbonate increased
from 50.8 to 81.1% during the study period, due to the
individualized prescription of bicarbonate dialysate con-
centration. The EBPG guidelines recommend that the
mid-week predialysis serum bicarbonate levels should be
maintained at 20–22 mmol/l [13]. A target range between
20 and 24 mmol/l was used in this study. A U-shape
relationship between serum bicarbonate and mortality or
hospitalization has been demonstrated in hemodialysis
patients in the DOPPS study [29]. After adjustment for
numerous comorbidities and for nutritional markers, the
lowest risk for mortality was observed with serum bicar-
bonate between 20.1 and 21 mmol/l and the lowest risk
for hospitalization was observed for serum bicarbonate
levels between 21.1 and 22 mmol/l. In this study, there
was an inverse correlation between pre-dialysis serum
bicarbonate and albuminemia, suggesting that the lower
bicarbonate concentrations resulted from greater acid load
caused by protein intake. Moderate predialysis acidosis
may be associated with better nutritional status, which is
strongly associated with increased survival in hemodialysis
patients. Patients with persistent and severe metabolic
acidosis may be treated by increasing the bicarbonatedialysate concentration or with oral sodium bicarbonate.
Patients with serum bicarbonate levels higher than the
upper target range can be treated by lowering the
bicarbonate dialysate concentration, bearing in mind
that intradialytic alkalosis is poorly tolerated with more
hypotensive episodes during the dialysis sessions [30].
Dyslipidemia management
Using dyslipidemia to define a quality-of-care indicator
is unlikely to be clinically relevant, for several reasons.
First, there is an inverse association of total cholesterol
with mortality in dialysis patients [31], probably due to
the cholesterol-lowering effect of systemic inflammation
and malnutrition. Secondly, the only two large trials that
studied the effects of statins in haemodialysis patients
did not show any beneficial effect on cardiovascular
death [32,33]. In a post-hoc analysis of the 4D trial
(Die Deutsche Diabetes Dialyse Study), high levels of
LDL-cholesterol showed a tendency to increase the risk
of cardiac endpoints and all-cause mortality. In patients
with a baseline LDL-cholesterol greater than 1.45 g/l
atorvastatin significantly decreased adverse fatal and
non-fatal cardiac events and all-cause mortality, compared
to placebo. As low serum cholesterol levels are associated
with increased mortality, this indicator was not chosen as
a « quality-of-care » indicator. Maybe cholesterol should
be used to identify patients who need statins, ie patients
with high LDL-cholesterol (> 1.45 g/l). Of course, statins
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ment before initiation of dialysis for a cardiac event [32].
Bone metabolism
The conformity rate for serum calcium targets was stable
around 60% during the study period despite the use of
calcimimetics or low dialysate calcium concentration; it
was above that observed in the national data system for
bone metabolism (52%, Observatoire Photo-graphe ;
n = 11172 patients) [34]. Recent KDIGO guidelines
introduced new targets [12]. Despite a lack of evidence
from randomized controlled trials demonstrating that
attaining serum calcium targets impacts clinical outcome,
large observational studies showed that the inflection
point at which calcium becomes associated with an
increased relative risk of all-cause mortality varies among
studies, from 2.38 to 2.85 mmol/l [35-37]. In an observa-
tional study in incident hemodialysis patients, hypocalce-
mia < 2.20 mmol/l was independently associated with
mortality (RR 2.10) [38]. Chronic hypocalcemia was
significantly associated with both de novo and recurrent
ischemic heart disease, and de novo and recurrent cardiac
failure. Thus, the KDIGO lower and upper thresholds for
calcium could be adapted, but one may argue that with
this new target range, the mean serum calcium level will
increase, and that high levels of Ca-P product may favor
vascular calcification [39].
In France, the conformity rate for serum phosphorus
and the mean serum phosphate level were 52% and
1.56 mmol/l in June 2009, respectively (Observatoire
Photo-graphe data). The mean serum phosphate level
was lower in our study, probably because of the increased
prevalence of malnutrition. The percentage of conformity
for serum phosphorus improved during the follow-up,
up to 72.3% in October 2009. The wider use of
hemodiafiltration may partially explain this result, since
we observed a trend towards lower serum phosphorus in
hemodiafiltration patients. Two large prospective observa-
tional studies showed that this dialysis modality could
improve phosphate control [40,41]. In the study of
Lars Penne et al., the proportion of hemodiafiltration
(HDF) patients with pre-dialysis phosphate concentra-
tions < 1.78 mmol/l increased from 64% to 74% during
the 6-month study period and was stable in hemodialysis
patients. Nevertheless, two RCTs did not show any benefit
of HDF on phosphate control, maybe because of the low
baseline phosphate levels (1.58 mmol/l et 1.62 mmol/l)
[42,43]. There is no evidence from RCTs that lowering
serum phosphorus to a specific target range reduces
mortality in hemodialysis patients. The target range for
phosphorus was modified with the publication of the
KDIGO clinical practice guidelines. The current target is
between 0.9 and 1.5 mmol/l [12]. Our conformity rate will
decrease with this new target range. Thus, more aggressivestrategies will have to be adopted to lower serum
phosphorus, such as adding a convective component
to clearance with hemodiafiltration, lengthening dialysis
session time or increasing dialysis frequency.
Vitamin D management
Because of the limited sunlight exposure in Normandy, our
patients are systematically supplemented with 25OHvitD.
Nevertheless, our conformity rate for vitamin D was
not satisfactory, with important variations considering
the mean vitamin D levels. Increasing evidence sugsests
that Vitamin D deficiency is an independant risk factor
for cardiovascular events and all-cause mortality in
hemodialysis patients [44,45]. In the 2009 KDIGO
guidelines, repeated measurements of 25OHvitD and
therapeutic supplementation in case of deficiency are
recommended [12]. A randomized controlled trial should
be performed to clarify whether vitamin D supplementation
can decrease adverse outcomes. Thus, vitamin D may
become an important quality-of-care indicator in the
near future.
Parathormone
In France, the conformity rate for PTH and the mean
serum PTH level were 33% and 317 pg/ml in June 2009
respectively (Observatoire Photo-graphe data), whereas
prevalence of conformity for PTH increased from 22%
to 42.8% in our study. According to recent KDIGO
guidelines PTH levels should be maintained in the range
of approximately two to nine times the upper normal
limit for the assay (45 to 490 pg/ml) [12]. Observational
data demonstrated that the K/DOQI treatment goals
were not easily achieved or maintained with traditional
therapeutic options (phosphate binders, vitamin D analogs)
for secondary hyperparathyroidism (SHPT). Moe et al.
performed a secondary analysis of three large RCTs,
demonstrating that cinacalcet effectively reduces PTH,
calcium, and phosphorus to the K/DOQI target ranges
in hemodialysis patients with SHPT [46]. In 2010, Block
et al. showed in a prospectively designed observational
study a significant survival benefit associated with
prescribing cinacalcet for hemodialysis patients with
evidence of SPHT and receiving i.v. vitamin D [47]. In
contrast, the recently published EVOLVE study found no
benefit to cinacalcet in hemodialysis patients and raised
significant safety issues [48].
Middle molecule removal management
An important improvement concerning the conformity
rate for β2M was noticed, which increased from 28.2%
to 48.5%. β2-microglobulin (β2M) is a marker for middle
molecules in uremia and a potential target for adequacy
in hemodialysis therapy. In 1704 patients from the
HEMO study, pre-dialysis serum β2M levels > 27.5 mg/l
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increased the use of hemodiafiltration with ultrapure
dialysate, which is the most efficient therapy to reduce
serum β2M levels, we expected a better conformity rate
for β2M. Indeed, convective treatments are an established
therapy to enhance uremic toxin removal over a wide
molecular-weight spectrum. Maduell et al. found mean
β2-microglobulin reduction rates were 75.4% for on-line
post-dilution hemodiafiltration versus 60.1% for high-flux
hemodialysis [50]. They also showed that short daily
on-line hemodiafiltration was associated with lower
pre-dialysis serum β2-microglobulin levels [51]. In
addition, dialyzers with better β2M clearance may be a
therapeutic option, although there may be an associated
risk of greater albumin loss.
Intradialytic hypotension management
The percentage of dialysis sessions with intradialytic
hypotension (IDH) remained low during the study period,
around 12%. Mortality in patients with frequent IDH is
significantly higher than in those without such events, but
after adjustment for covariates, this association loses
significance [52]. Thus, IDH may represent a marker of
comorbid conditions. Our in-center dialysis study failed to
demonstrate a substantial improvement for this indicator,
despite many measures systematically followed to improve
hemodynamic instability, perhaps because it was already
very low. The dry weight was assessed by clinical examin-
ation with the help of bioimpedance measurements, using
the BCM. We checked in those patients with frequent IDH
that sodium restriction and timing of antihypertensive
agents were well respected. More than 90% of the patients
during the study period were treated with isothermic
dialysis, that was shown to improve hemodynamic in-
stability, as well as dialysis at cooler dialysate temperatures
[9,53]. The percentage of patients on on-line post-dilution
hemodiafiltration increased during the study. This
convective technique was associated with a significant
reduction of hypotensive episodes, predominantly related
to decreased body temperature [54]. In the EBPG guide-
lines on hemodynamic instability, convective techniques
are a possible alternative to cool dialysis. If these treatment
options have failed, other available therapies are suggested:
midodrine (level 1 evidence), blood volume controlled
ultrafiltration, use of a dialysate calcium of 1.5 mmol/l,
prolongation of dialysis time or increase in dialysis
frequency (level 2 evidences), L-carnitine supplementation,
and/or bicarbonate dialysis (level 3 evidences) [55].
The importance of quality-of-care indicators is well
established. Some indicators, as defined by international
guidelines, rely on a solid scientific basis with clear
associations with outcomes (hemoglobin, albumin, dialysis
dose, vascular access). Nevertheless, the clinical advantage
of meeting multiple treatment targets simultaneouslyremains to be established. In addition cost/benefit evalua-
tions of each indicator, and especially of strategies based on
multiple quality-of-care indicators should be performed.
In hemodialysis patients, the association between several
indicators, such as phosphate, BP or BMI, and mortality
is characterized by a J-shaped curve. In this context,
which quality-of-care indicator should be prioritized
may be a matter of debate. In addition, regarding several
routinely measured parameters, such as 25OHvitaminD
or β2-microglobulin, evidence for specific targets and
guidelines are lacking, suggesting that locally determined
targets may be useful before RCTs and evidence-based
guidelines are available.
Conclusions
In conclusion, this study shows that following quality-
of-care indicators can improve clinical practice by
highlighting center-specific weaknesses, prompting the
establishment of corrective measures. Our work points
out the difficulty of using standardized targets for
quality-of-care indicators. We suggest that indicators
based on scientific evidence should be prioritized, and that
the definition and targets of some indicators, especially
hypertension and LDL-cholesterol, be reviewed, since
evidence of their association with mortality is not clearly
demonstrated.
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